Patent Expiry
MNKD: TYVASO DPI: recorded patent 11826327 expiry
February 3, 2042 · TREPROSTINIL. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- February 3, 2042
- Company
- MANNKIND CORP (MNKD)
- Drug
- TREPROSTINIL
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Patent Expiry
TYVASO DPI: recorded patent 11826327 expiry
Orange Book application NDA214324, product 001, listed patent 11826327 expiry. Overall loss of exclusivity and current company rights: unknown.FDA source
- Company
- MANNKIND CORP (MNKD)
- Drug
- TREPROSTINIL